• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Benefits May Persist After Antihypertensive and Statin Treatment
Patients with hypertension may benefit from antihypertensive treatment with a calcium channel blocker and a lipid-lowering statin years after taking the medications, reported a long-term follow-upstudy in theLancet. Patients who received amlodipine-based antihypertensive treatment had fewer stroke deaths —independent of blood pressure levels—and patients taking lipid-lowering atorvastatin had fewer cardiovascular deaths.
Source: JAMA - October 23, 2018 Category: General Medicine Source Type: research

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
Publication date: Available online 26 August 2018Source: The LancetAuthor(s): Ajay Gupta, Judith Mackay, Andrew Whitehouse, Thomas Godec, Tim Collier, Stuart Pocock, Neil Poulter, Peter SeverSummaryBackgroundIn patients with hypertension, the long-term cardiovascular and all-cause mortality effects of different blood pressure-lowering regimens and lipid-lowering treatment are not well documented, particularly in clinical trial settings. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study reports mortality outcomes after 16 years of follow-up of the UK participants in the original ASCOT trial.MethodsASCOT was...
Source: The Lancet - August 26, 2018 Category: General Medicine Source Type: research

Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study
In this study, 5857 patients received coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. There were no differences in comorbidity or use of antihypertensive drugs between patients who received CYP3A4-metabolized statins and those who received non-CYP3A4-metabolized statins. Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury (adjusted odds ratio [OR] = 2.12; 95% CI = 1.35–3.35), hyperkalemia (adjusted OR = 2.94; 95% CI = 1.36–6.35), acute myocardial infarction (adjusted OR = 1.55; 95% CI = 1.16–2.07), and acute ischemic ...
Source: Medicine - January 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research